ArticleBMJ paediatrics open2025
Paediatric Stevens-Johnson syndrome and toxic epidermal necrolysis: patterns and outcomes in a retrospective Pakistani cohort.
Article in BMJ paediatrics open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A Pediatric Case of Stevens-Johnson Syndrome With Extensive Palmoplantar Involvement Following Varicella Infection.Cureus · 2026Article
- Case Report: Stevens-Johnson syndrome/toxic epidermal necrolysis overlap with ocular and urogenital involvement in an extremely preterm infant following broad-spectrum antibiotic exposure.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but severe mucocutaneous reactions in children, often triggered by medications such as antibiotics, anticonvulsants and non-steroidal anti-inflammatory drugs (NSAIDs). Treatment guidelines in paediatric populations remain unclear, particularly in South Asia, where data are scarce. This study aims to describe the clinical profile, triggers, management and outcomes of paediatric SJS/TEN cases from a tertiary care centre in Pakistan.
methodsA retrospective cross-sectional study was conducted at Aga Khan University Hospital, Karachi, Pakistan. Medical records of children aged 1 month to 15 years diagnosed with SJS or TEN between June 2008 and December 2020 were reviewed. Data on demographics, drug exposure, clinical features, treatment modalities and outcomes were extracted and analysed using Stata V.14.
resultsAmong 124 identified cases, 98 children (79.0%) had TEN with >30% body surface area involvement. Mucosal involvement was seen in 85 (68.5%) cases. Prior drug exposure was documented in 98 (79.0%) patients, with antibiotics (52.0%) and NSAIDs (48.0%) being the most common triggers. Supportive care was the mainstay of treatment. Age was associated with poorer outcomes.
conclusionPaediatric drug-induced SJS/TEN remains a critical concern, particularly due to commonly prescribed antibiotics and NSAIDs. High mortality in TEN cases and predominant use of supportive therapy highlight the need for clear paediatric treatment protocols. Local data on the role of early immunomodulatory therapy are limited, indicating a need for further research on optimal early interventions to improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.